small molecule

KERYDIN

TAVABOROLE

Loss of exclusivityloss of exclusivity
CompanyAnacor PharmaceuticalSee this company's full patent-cliff portfolio

Drug detail

Brand nameKERYDIN
Active ingredientTAVABOROLE
Strength5% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formSOLUTION
RouteTOPICAL
ModalitySmall molecule
FDA approvalJuly 2014
Marketing statusDISCN

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

KERYDIN patent cliff — loss of exclusivity — | CliffBio